Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial

Núñez, Marina; Miralles, Celia; Angel Berdún, Miguel; Losada, Elena; Aguirrebengoa, Koldo; Ocampo, Antonio; Arazo, Piedad; Cervantes, Manuel; de los Santos, Ignacio; San Joaquín, Isabel; Echeverría, Santiago; José Galindo, María; Asensi, Víctor; Barreiro, Pablo; Sola, Julio; José Hernandez-Burruezo, Juan; M. Guardiola, Josep; Romero, Míriam; García‐Samaniego, Javier; Soriano, Vincent; Behalf Of The PRESCO Study Group, On

doi:10.1089/aid.2007.0011

Public

Role of Weight-Based Ribavirin Dosing and Extended Duration of Therapy in Chronic Hepatitis C in HIV-Infected Patients: The PRESCO Trial

Published in AIDS Research and Human Retroviruses • Aug 1, 2007

Authors:

Marina Núñez

Celia Miralles

Miguel Angel Berdún

Abstract

The response to pegylated interferon (pegIFN) plus ribavirin (RBV) as treatment of chronic hepatitis C virus (HCV) infection is lower in HIV-coinfected than in HCV-monoinfected patients and could be due to suboptimal RBV dosing and/or insufficient duration of therapy in prior trials. In a prospectiv...

Subject

Ribavirin

Dosing

Chronic hepatitis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!